# US 2023/0272407 A1 · Composition and Method of an Orally Administered Antimicrobial Peptide Vectored in a Bacterial Expression Vehicle

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272407 A1
- Document ID: US20230272407A1
- Status: Published application
- Kind: A1
- Application number: 18/008,512
- Filed: 2021-06-14
- Published: 2023-08-31
- Earliest claimed: 2020-06-18
- Assignees: US Biologic, Inc.; The United States of America as represented by the Secretary of Agriculture
- Applicants: US Biologic, Inc.; The United States of America as represented by the Secretary of Agriculture
- Inventors: Jolieke Gerdy van Oosterwijk; Luciana Meirelles Richer; Douglas Steven Zatechka; Woohyun Kim; Hyun Soon Lillehoj; Cyril Gray; Christopher Anthony Przybyszewski
- Web page: https://patentgrep.com/patent/US20230272407A1

## CPC

- C12N 15/75: for Bacillus
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- C07K 14/465: from birds
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The inventive subject matter includes an antimicrobial peptide vectored composition made of a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules. More specifically these novel recombinant antimicrobial peptide effector molecules exhibit preferential anti¬microbial activity. The utility of the current inventive subject matter has demonstrated a reduced viability of Eimeira acervulina sporozoites in vitro using a sporozoite killing assay. More specifically, the antimicrobial peptide vectored composition is a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules, wherein the one or more recombinant antimicrobial peptide effector molecules are engineered from a NK-lysin gene and the one or more recombinant antimicrobial peptide effector molecules are engineered to express functionally active NK-2.

## Claims

### Claim 1

A method to treat a subject in need of a treatment comprising:
orally administering a therapeutically effective amount of an antimicrobial peptide vectored composition comprising a bacterial protein expression vehicle comprised of a whole cell Bacillus subtilis transformed with a replicable plasmid DNA expression construct codon-optimized for expressing functionally active NK-2, wherein the subject is poultry and said poultry are in need of treatment for Avian coccidiosis, comprising the step of orally administering to the subject the therapeutically effective amount of the antimicrobial peptide vectored composition to induce cytotoxicity to treat an Avian coccidiosis infection.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is poultry and said poultry are in need of treatment to increase body weight, comprising the step of orally administering to the subject the therapeutically amount of a stable strain of a probiotic B. subtilis expressing cNK-2 to increase body weight of said subject.

### Claim at position 4

-16. (canceled)
